Original ResearchPublished 9 January 2026Hepatobiliary adverse drug reactions during treatment with olaparib: an analysis of data from the EudraVigilance reporting systemElena-Mirabela Velişcu · Cecilia Cagnotta · Maria Giuseppa Sullo · Antonietta Anatriello · Francesco Salvo · Cristina ScavoneFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2025.1736759
ReviewPublished 26 November 2025Discrepancies in regulations in post-marketing safety surveillance of drug-device combination products in the EU and US: a reviewJoan D’souza · Mukesh Nandave · Ruth BlöchlingerFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2025.1609455
